Navigation Links
40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)

- One Outstanding Student to Become the SolvayCARES Thriving Student

Achiever and Receive $10,000 to Further Academic Goals -

MARIETTA, Ga., Sept. 15 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. has awarded scholarships totaling $100,000 to 40 students living with cystic fibrosis (CF) through its SolvayCARES Scholarship program. Each student has received a one-year award of $2,500 to help finance post-secondary education. This fall, one SolvayCARES Scholarship winner will go on to earn the title of "Thriving Student Achiever" through an online voting process at and be honored with a scholarship totaling $10,000.

Cystic fibrosis presents extraordinary health burdens for patients and financial challenges for their families. Thanks to tremendous advances in medical treatments, more young adults with CF are living longer, healthier lives than ever before, and many more are pursuing dreams of higher education. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States. Today, more than 40 percent of people living with CF are aged 18 or older.(1)

For 16 years, Solvay Pharmaceuticals has awarded scholarships to high-achieving students with CF to encourage their pursuit of educational goals. The Scholarship is one aspect of the SolvayCARES program, which was created to address the specific needs of this patient population by providing support in a variety of formats throughout their lives as patients' needs evolve with age -- such as upon graduation from high school.

"The SolvayCARES Scholarship helped ease the financial responsibility of my higher education and allowed me to focus on what really matters -- earning my doctoral degree in clinical psychology so that I can pursue my dream of working in clinical therapy with individuals affected by chronic illnesses and those connected to them," said Samantha Pelican Monson, a 2007 SolvayCARES Scholarship recipient and doctoral student at the University of Denver. "With a little creativity, you can overcome any obstacle, health-related or otherwise, and achieve the goals and dreams you have always wished would come true."

This year's SolvayCARES Scholarship program offers a new opportunity with the launch of the Thriving Student Achiever award. This winner will earn a total of $10,000 in scholarship funding and will be determined through an online voting process open to the general public at This site will feature the profiles, winning essays and creative presentations of all Scholarship recipients who choose to be considered for the Thriving Student Achiever award. Friends of the CF community and the general public are encouraged to log on to learn more about these students' remarkable accomplishments and vote for their favorite scholarship recipient. Online voting will be available from September 15 to October 15, at which time the Thriving Student Achiever will be determined.

"At Solvay Pharmaceuticals, we believe that reaching the milestone of graduation signifies tremendous victory for young people with CF and their families, and demonstrates courage and commitment," said Dr. Stephen Hill, president and chief executive officer of Solvay Pharmaceuticals, Inc. "For the sixteenth consecutive year, we are proud to support this deserving and dynamic group of young people in attaining their next academic success. Our hope is that featuring winners' stories online will result in an increased awareness of CF and a heightened appreciation of these students' accomplishments."

Winners of the SolvayCARES Scholarship and Thriving Student Achiever award receive a one-year scholarship for post-secondary study of any kind through an accredited program; winners' courses of study can range from vocational school to undergraduate degrees to doctoral work. Winners are determined through an application process focusing on creativity, academic excellence, community involvement, ability to serve as a role model in the CF community and financial need. Applications are due in early summer each year and the application form can be viewed via the SolvayCARES Scholarship Web site.

About SolvayCARES(SM)

For more than 20 years, Solvay Pharmaceuticals has supported the CF community through SolvayCARES programs that offer nutritional, educational and financial resources. This support is provided at no cost to patients and includes: free CREON(R) (Pancrelipase Delayed-Release Capsules, USP) and multivitamins to patients for the first three years of life; nutritional drink supplements and multivitamins for children, teenagers and adults; and educational resources that address patients' evolving needs as they enter different life stages. Since 1993, Solvay Pharmaceuticals has awarded more than 500 scholarships for post-secondary education, totaling more than $1.7 million in educational funding. SolvayCARES also offers financial support through a Patient Assistance Program for patients who meet established financial criteria. To learn more about the nutritional, educational and financial support available through SolvayCARES, please visit For full safety and prescribing information about CREON(R), visit

About Solvay Pharmaceuticals, Inc.

Solvay Pharmaceuticals Inc., of Marietta, Ga., is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit

Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, and men's and women's health. Its 2007 sales were EUR 2.6 billion and it employs more than 9,000 people worldwide. For more information, visit

SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at


(1) Cystic Fibrosis Foundation. About Cystic Fibrosis. Accessed August 2008.

Contact: Neil Hirsch

Manager, U.S. Corporate Communications

Solvay Pharmaceuticals, Inc.


Jane Petrino

Senior Account Supervisor

Ruder Finn


SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CCMR gets $2.9M for training grad students in nanoscale science
2. CCMR gets $2.9M for training grad students in nanoscale science
3. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
4. UCB Crohns Scholarship Program to Award $300,000 to Students with Crohns Disease
5. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
6. Connecticut BioBus Travels to State Capitol on April 24 for Tours and Experiments with Visiting Students
7. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
8. Pittsburgh Region Middle School Students Participate in Hands-on Tissue Engineering Summer Camp
9. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
10. US College Students Needing TB Testing Now Have the Benefit of QFT(TM)
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
(Date:11/30/2015)... 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") ... Wong to its Board of Directors to replace Dr. ... a wealth of experience as co-founder of Resverlogix, with expertise ... --> --> Dr. Wong remarked, "I ... directors. Zenith,s long standing expertise in epigenetics and the advanced ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to announce ... offered in symposia, oral sessions, workshops, awards, and posters. The core of ... applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food ...
Breaking Biology Technology:
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
Breaking Biology News(10 mins):